

**Jin-Pok Kim Memorial Lecture**

Thursday, October 19 13:35~13:55

Room18 (301, 3F, Conference Center, Pacifico Yokohama)

Chair : Kazuhiro Yoshida Gifu University

**M** The Asia-Pacific region's growing role in the fight against cancer

Yuhan Corporation, Republic of Korea Yeul-Hong Kim

**AOS Symposium 1**

Thursday, October 19 9:10~10:10

Room18 (301, 3F, Conference Center, Pacifico Yokohama)

**AI oncology in Asian countries**

Chair : Yoshihiro Kakeji Gastroenterological Surgery, Kobe University

Zeba Aziz Medical Oncology Department, Hameed Latif Hospital,  
Islamic Republic of Pakistan**AOSS-1-1** Artificial intelligence-based spatial analysis of Tertiary Lymphoid Structures (TLSs) and the antitumor effect of immune checkpoint inhibitor for endometrial cancerDepartment of Gynecology and Obstetrics,  
Kyoto University Graduate School of Medicine Junzo Hamanishi**AOSS-1-2** Development of a machine learning model to evaluate changes during radiotherapy in cervical cancer tumor cellsDepartment of Radiation Oncology, Institute of Medicine, University of Tsukuba  
Masaaki Goto**AOSS-1-3** Predictive value of dynamic contrast-enhanced-MRI-based machine learning model for lymphovascular invasion status in node-negative invasive breast cancerDepartment of Breast Imaging,  
Tianjin Medical University Cancer Institute & Hospital,  
National Clinical Research Center for Cancer, People's Republic of China  
Rong Liang**AOSS-1-4** Deep neural networks on prediction of pathological invasiveness of pulmonary nodules through GAN-based synthetic PET from CT imageDepartment of Thoracic Surgery, Guangdong Provincial People's Hospital  
(Guangdong Academy of Medical Sciences),  
Southern Medical University, People's Republic of China Lintong Yao

**AOSS-1-5** An excellent Application of Deep Learning in breast cancer diagnosis with Hematoxylin and Eosin stained breast tissue Images of Vietnamese patients

Cancer Research and Clinical Trials Center, Vietnam National Cancer Hospital,  
Socialist Republic of Viet Nam/  
Vietnam National Cancer Hospital, Socialist Republic of Viet Nam/  
Hanoi Medical University, Socialist Republic of Viet Nam Tu Van Dao

**AOS Symposium 2**

Thursday, October 19 13:55~14:35

Room18 (301, 3F, Conference Center, Pacifico Yokohama)

**Perspective of AOS -Presidential keynote speech**

Chair : Yeul-Hong Kim Yuhan Corporation, Republic of Korea

Ying Wang China Anti-Cancer Association (CACA), People's Republic of China

**AOSS-2-1** Future perspective and the roadmap of AOS  
-the way to go-

Gastroenterological Surgery, Postgraduate school of Medicine, Gifu University  
Kazuhiro Yoshida

**AOSS-2-2** Development of Holistic Integrative Management of  
Cancer in China

China Anti-Cancer Association (CACA), People's Republic of China Ying Wang

**AOS Symposium 3**

Thursday, October 19 14:45~16:15

Room18 (301, 3F, Conference Center, Pacifico Yokohama)

**Cancer genomics in Asian countries**

Chair : Manabu Muto Department of Therapeutic Oncology,

Graduate School of Medicine, Kyoto University

Herdee Gloriane Cristal Luna Cancer Institute, St. Luke's Medical Center/  
Section of Medical Oncology,  
National Kidney and Transplant Insititute,  
Republic of the Philippines

**AOSS-3-1** Feasibility of next generation sequencing-based cancer  
gene panel analysis using formalin-fixed, paraffin-  
embedded biopsies of gastric cancer

Department of Gastroenterological Surgery,  
Nagoya University Graduate School of Medicine Mitsuro Kanda

**AOSS-3-2** Comprehensive genomic profiling before first-line set-  
ting provides more opportunities of treatment than after  
standard of care in patients with advanced solid tumors:  
the prospective FIRST-Dx study

Kyoto University Hospital Junichi Matsubara

- AOSS-3-3** Clinical utility of cancer whole-genome and transcriptome sequencing for precision diagnosis of hepatobiliary and esophageal cancers  
Laboratory for Cancer Genomics, RIKEN IMS Hidewaki Nakagawa
- AOSS-3-4** RNA editing is a valuable biomarker for predicting carcinogenesis in ulcerative colitis  
Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences Kunitoshi Shigeyasu
- AOSS-3-5** Multi-omics Characterization of Cholangiocarcinoma Reveals Distinct Prognostic and Therapeutic associated Molecular Subtypes  
Tianjin Medical University Cancer Institute & Hospital, People's Republic of China  
Lu Chen
- AOSS-3-6** Large-scale cancer genomic analysis reveals significant disparities between microsatellite instability and tumor mutational burden  
Division of Oncology/Hematology, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Republic of Korea Jungyoon Choi

#### **AOS Symposium 4**

Friday, October 20 8:30~10:00

Room18 (301, 3F, Conference Center, Pacifico Yokohama)

#### **Recent Clinical Trial Design in Asian Countries - including Digital Transformation**

Chair : Takayuki Yoshino National Cancer Center Hospital East  
Jen-Shi Chen Hematology-Oncology, Linkou Chang Gung Memorial Hospital, Taiwan

- AOSS-4-1** Lazertinib vs Gefitinib in Treatment-Naïve Patients with EGFR-mutated NSCLC: LASER301 Asian Subpopulation Analysis  
Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Kingdom of Thailand  
Thanyanan Reungwetwattana
- AOSS-4-2** Pediatric Hepatic International Tumors Trial (PHITT) in Asia  
Natural Science Center for Basic Research and Development, Hiroshima University/  
Pediatric Surgery, Hiroshima University Hospital Eiso Hiyama
- AOSS-4-3** Multi-cycle prophylaxis of long-acting granulocyte colony-stimulating factor in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy: A retrospective real-world study  
Harbin Medical University Cancer Hospital, People's Republic of China  
Yanqiao Zhang

**AOSS-4-4** Consistency of Risk Assessment of Chemotherapy-Induced Febrile Neutropenia and Compliance with Guidelines for G-CSF Prophylaxis and Treatment in China: A Retrospective Real-World Study

Breast Internal Medical Department, Hunan Cancer Hospital,  
People's Republic of China Quchang Ouyang

**AOSS-4-5** COST EFFECTIVENESS OF TREATMENT FREE REMISSION IN CHRONIC MYELOID LEUKEMIA-REPORT FROM A DEVELOPING COUNTRY

Department of Oncology, Hameed Latif Hospital, Islamic Republic of Pakistan  
Alishba Asif

**AOSS-4-6** A Phase III Randomized Controlled Trial in Primary Stage Three and Four Ovarian Cancer After Interval Cytoreductive Surgery (FOCUS)

Center for Gynecologic Cancer, Research Institute and Hospital, National Cancer Center, Republic of Korea Ji Hyun Kim

## AOS Symposium 5

Friday, October 20 13:55~15:25

Room18 (301, 3F, Conference Center, Pacifico Yokohama)

### Current status of minimally invasive surgery (non-robot) in Asian countries

Chair : Minoru Tanabe Tokyo Medical and Dental University

Woo Yong Lee Department of Surgery, Samsung Medical Center

**AOSS-5-1** Limited oncological benefits of laparoscopic total gastrectomy with splenectomy for patients with type 4 or large type 3 gastric cancer

Department of Surgery, Kyoto City Hospital/Department of Surgery,  
Japanese Red Cross Osaka Hospital Masazumi Sakaguchi

**AOSS-5-2** Removing the esophageal stump during reconstruction for esophagojejunostomy in total gastrectomy for gastric cancer: easy and safe modified overlap method for minimally invasive surgery

Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences/Department of Surgery, Tsuyama  
Chuo Hospital Yoshihiko Kakiuchi

**AOSS-5-3** Withdrawn

**AOSS-5-4** Randomized Controlled Trial Comparing the Short-term Outcomes of Enhanced Recovery After Surgery and Conventional Care in Laparoscopic Distal Gastrectomy (GISSG1901)

The Affiliated Hospital of Qingdao University, People's Republic of China  
Yulong Tian

**AOSS-5-5** Our first 31 cases of rectal cancer treated with Trans anal total mesorectal excision (TaTME) -The short-term outcomes of a single educational hospital in Japan-  
Department of General Surgery, The University of Gunma Ikuma Shioi

**AOSS-5-6** The challenging of pediatric ovarian tissue cryopreservation with an updated version of the Edinburgh criteria for appropriate patient selection  
Department of Obstetrics and Gynecology, St. Marianna University School of Medicine  
Seido Takae

## AOSS Symposium 6

Friday, October 20 15:35~17:05

Room18 (301, 3F, Conference Center, Pacifico Yokohama)

### Current status of radiation oncology in Asian countries

Chair : Hideyuki Sakurai University of Tsukuba

Jinsil Seong Department of Radiation Oncology, Yonsei Cancer Center,  
Yonsei University Medical College, Republic of Korea

**AOSS-6-1** Brachytherapy in treating early-stage nasopharyngeal cancer in Viet Nam  
Department of Head and Neck Radiation, Ho Chi Minh City Oncology Hospital,  
Socialist Republic of Viet Nam Hien Thi Bich Nguyen

**AOSS-6-2** A Case of Rectal Leiomyosarcoma Successfully Treated with Surgery and Adjuvant Radiotherapy  
Department of Radiation Oncology, Gil Medical Center,  
Gachon University College of Medicine, Republic of Korea Seok Ho Lee

**AOSS-6-3** Adding Intensity Modulated Radiotherapy to Postoperative Chemotherapy after Total Mesorectum Excision in pT3N0 Proximal Rectal Carcinoma  
Department of Radiation Oncology, Ditmanson Medical Foundation  
Chia-Yi Christian Hospital, Taiwan Yuwen Wang

**AOSS-6-4** PET/CT-guided thoracic radiation therapy is associated with improved clinical outcomes of patients with metastatic central lung squamous cell carcinoma: a propensity score-matched analysis  
Department of Radiotherapy, Cancer Hospital of China Medical University,  
Liaoning Cancer Hospital and Institute, People's Republic of China Ye Wang

**AOSS-6-5** Association between smoking status and the prognosis of brain metastasis in patients with non-small cell lung cancer  
Department of Radiotherapy, Liaoning Cancer Hospital & Institute,  
People's Republic of China Tianlu Wang

**AOSS-6-6** Should RT dose be adjusted based on systemic therapy? What we learned from cervical cancerDepartment of Radiology / Radiation Oncology, Nagoya University Hospital  
Mariko Kawamura**AOS Symposium 7**

Saturday, October 21 8:30~9:30

Room18 (301, 3F, Conference Center, Pacifico Yokohama)

**Current status of robot-assisted surgery in Asian countries**Chair : Ichiro Takemasa Department of Surgery, Surgical Oncology and  
Science, Sapporo Medical UniversityHan Kwang Yang Seoul National University Hospital & Seoul National University  
College of Medicine, Republic of Korea**AOSS-7-1** Safety and feasibility of minimally invasive pancreaticoduodenectomyDepartment of Gastroenterological Surgery, Graduate School of Medical Sciences,  
Kumamoto University Kosuke Kanemitsu**AOSS-7-2** Experience of robot-assisted laparoscopic radical prostatectomy using hinotori surgical robot system

Department of Urology, Keio University School of Medicine Rei Kamitani

**AOSS-7-3** Withdrawn**AOSS-7-4** Establishment of robot assisted retroperitoneal radical nephroureterectomyDepartment of Urology, Osaka University Graduate School of Medicine  
Atsunari Kawashima**AOS Symposium 8**

Saturday, October 21 9:45~10:45

Room18 (301, 3F, Conference Center, Pacifico Yokohama)

**Optimization of the system of medical care and research for hereditary tumors**Chair : Yasuhiro Kodera Department of Gastroenterological Surgery,  
Nagoya University Graduate School of Medicine

Corazon A Ngelangel Philippine Cancer Society, Republic of Philippines

**AOSS-8-1** ADOLESCENTS AND YOUNG ADULTS BREAST CANCER SURVIVORS' NEEDS OF HEALTHCARE AND SOCIAL RE-INTEGRATION AFTER TREATMENTDepartment of Medical Oncology 4, Ho Chi Minh city Oncology Hospital,  
Socialist Republic of Viet Nam Kim Minh Nguyen**AOSS-8-2** Knowledge, Attitudes, and Practices in Colorectal Cancer Screening in the PhilippinesUniversity of the Philippines - Philippine General Hospital, Republic of the Philippines  
Joseff Karl Uy Fernandez

**AOSS-8-3** Understanding Psychological distress in patients prior to breast cancer diagnosis: Mixed Methods Study

Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital,  
Third Hospital of Shanxi Medical University, People's Republic of China Yan Gao

**AOSS-8-4** TREATMENT DIFFICULTIES IN OLD BREAST CANCER PATIENTS IN A RESOURCE LIMITED SETTING

Department of oncology, Hameed Latif Hospital, Islamic Republic of Pakistan  
Kaynat Fatima

**AOSS-8-5** Enriched environment and the potential psychobiotic *Lactobacillus spp.* suppress pancreatic cancer growth via gut microbiome modulation.

State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute,  
Renji Hospital, Shanghai Jiao Tong University School of Medicine,  
People's Republic of China Yiyi Liang

**AOS Symposium 9**

Saturday, October 21 13:30~15:00

Room18 (301, 3F, Conference Center, Pacifico Yokohama)

**Cancer immunotherapy in Asian countries**

Chair : Koji Kono Department of Gastrointestinal Tract Surgery,  
School of Medicine, Fukushima Medical University

Tarini Sahoo Silverline Hospital and Research Institute, Republic of India

**AOSS-9-1** Real-World Outcomes of Pembrolizumab, Nivolumab and Atezolizumab Efficacy in Korea Veterans with Advanced Stage IV Non-Small-Cell Lung Cancer

Division of Hematology-Oncology, Department of Internal Medicine, Veterans Health Service Medical Center, Republic of Korea/Division of Hematology-Oncology, Department of Internal Medicine, Ewha Womans University Medical Center, Ewha Womans University College of Medicine, Republic of Korea Ahrong Ham

**AOSS-9-2** Phase I/II clinical trial of nivolumab in combination with oligo-fractionated irradiation for patients with advanced gastric cancer

Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine/Department of Blood Transfusion and Transplantation Immunology, Fukushima Medical University School of Medicine Kosaku Mimura

**AOSS-9-3** Overcoming Tumor heterogeneity by T Cells Ex Vivo Armed with Multiple Bispecific Antibodies

Department of Pediatrics, Inha University Hospital, Republic of Korea/Pediatrics, Memorial Sloan Kettering Cancer Center, United States of America  
Jeong A Park

**AOSS-9-4** Real world Indian experience with combination of immunotherapy and VEGF tyrosine kinase inhibitor in first line metastatic renal cell carcinoma

Department of Medical Oncology, Manipal Hospital, Republic of India  
Amit Rauthan

**AOSS-9-5** Development of tumor-agnostic combination therapy with immune checkpoint inhibitors based on circulating tumor DNA genomic information  
Department of Urology, Osaka University Graduate School of Medicine  
Taigo Kato

**AOSS-9-6** ADC-Coated NK Cells: An Emerging Strategy for Combining Chemotherapy and Immunotherapy in Cancer Treatment  
Department of Smart Health Science and Technology convergence, College of ACE, Kangwon National University, Republic of Korea Hongbin Kim

**AOSS-9-7** Development of a spontaneously antibody-binding recombinant fusion protein system for immune cell surface modification and its application to HER2-positive cancer cells  
Department of Smart Health Science and Technology convergence, College of ACE, Kangwon National University, Republic of Korea Luna Kim

### ICGC-ARGO Session

Thursday, October 19 15:50~17:05  
Room17 (311+312, 3F, Conference Center, Pacifico Yokohama)

### ICGC-ARGO Cancer Omics and Precision Oncology

Chair : Takayuki Yoshino National Cancer Center Hospital East

**ICGC-ARGO** ★Abst Title★

所属確認中, United Kingdom Andrew V. Biankin

### AOS Oral Session 1

Thursday, October 19 8:40~9:50  
Room17 (311+312, 3F, Conference Center, Pacifico Yokohama)

### Basic research for gastric cancer

Chair : Tomoki Makino Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University

**AOSO-1-1** Epigenetic silencing of *miR-200* family is associated with regulation of *ZEB1/ZEB2* in gastric cancer metastasis  
Department of Surgery, Chonnam National University Medical School, Republic of Korea Dong Yi Kim

**AOSO-1-2** Down-regulation of stimulator of interferon genes (STING) expression and CD8<sup>+</sup> T-cell infiltration in HER2-positive gastric cancer  
Department of Gastrointestinal Tract Surgery, Fukushima Medical University  
Satoshi Fukai



- AOSO-1-3** Exosomal PKM2 induces macrophages alternative activation by SREBP1 and promotes gastric cancer progression  
 Jiangsu Province Key Laboratory of Tumor Systems Biology and Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, People's Republic of China Qingmin Sun
- AOSO-1-4** IQGAP3 maintains proliferative heterogeneity to enhance infra-tumoral oncogenic functions  
 Cancer Science Institute of Singapore, National University of Singapore, Republic of Singapore/Department of Surgery, Tohoku University Graduate School of Medicine Mitsuhiro Shimura
- AOSO-1-5** Hypoxia-related mitochondrial protein IREB2-268aa promotes gastric cancer progression through DHODH induced ferroptosis defense  
 Department of Gastrointestinal Surgery, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, People's Republic of China Zai Luo
- AOSO-1-6** Inhibition of gastric cancer by a new controlled releasing compound of TLR-7/8 agonist via immune activation in a gastric cancer xenograft mouse model  
 Cancer Research Institute, Seoul National University, Republic of Korea Hyun Myong Kim
- AOSO-1-7** Analysis of targetable neo-angiogenesis factors in hematogenous metastasis of gastric cancer using TCGA data  
 Cancer Research Institute, Seoul National University, Republic of Korea Jaemun Yoo

## AOS Oral Session 2

Thursday, October 19 13:25~14:35

Room17 (311+312, 3F, Conference Center, Pacifico Yokohama)

### Immune and nutrition in gastric cancer

Chair : Marie Cherry Lynn Smsen Fernando  
 Cancer Institute of the Manila Doctors Hospital, Republic of the Philippines

- AOSO-2-1** Albumin and derived neutrophil-to-lymphocyte ratio is a novel prognostic factor for patients with esophageal squamous cell carcinoma  
 Division of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University Tomoki Abe
- AOSO-2-2** Timing of the initial infusion of nivolumab for patients with recurrent or metastatic squamous cell carcinoma of the esophagus influences its efficacy  
 Department of Clinical Oncology, Kyoto University Hospital Motoo Nomura

- AOSO-2-3** The place of modified Docetaxel/Cisplatin/Fluorouracil in the era of immunotherapy as a first-line systemic therapy for metastatic esophageal cancer  
Department of Oncology, Hanoi Medical University, Socialist Republic of Viet Nam  
Anh Thi Kim Tran
- AOSO-2-4** Short outcomes of adjuvant immunotherapy for esophageal cancer in our institution  
Department of Gastroenterological Surgery, Okayama University  
Masashi Hashimoto
- AOSO-2-5** Exploring the Dichotomous Immune Microenvironment in Stomach Adenocarcinoma through Conventional Type 1 Dendritic Cells-Associated Risk Model  
Department of Pathology, Dong-A University College of Medicine, Republic of Korea  
Song-hee Han
- AOSO-2-6** Perioperative ghrelin administration attenuates postoperative skeletal muscle loss in patients who underwent esophagectomy for esophageal cancer  
Department of Gastroenterological Surgery, Osaka University, Graduate School of Medicine  
Kotaro Yamashita
- AOSO-2-7** Two case reports of immunotherapy followed by conversion surgery in metastatic gastric cancer  
Department of Oncology, Kaohsiung Chang-Gung Memorial Hospital, Taiwan  
Ming-chun Kuo

### AOS Oral Session 3

Thursday, October 19 14:45~15:35

Room17 (311+312, 3F, Conference Center, Pacifico Yokohama)

#### Case series (RWD) of colorectal cancer

Chair : Wataru Sakamoto Department of G-I Tract Surgery, Fukushima Medical University

- AOSO-3-1** Clinical outcomes of neoadjuvant therapy followed by selective inguinal lymph node dissection and total mesorectal excision for metastasised low rectal cancer  
Department of Surgery, Kobe University Graduate School of Medicine  
Hiroshi Hasegawa
- AOSO-3-2** Clinical Outcomes of Different Preoperative Treatment Strategies in Locally Advanced Rectal Cancer: Real world experience  
Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital Mahidol University, Kingdom of Thailand  
Jitlada Khonglim

- AOSO-3-3** Chemotherapy re-use is an effective strategy for third-line treatment of patients with metastatic colorectal cancer: a real-world cohort study  
Department of GI Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, People's Republic of China Jingjing Duan
- AOSO-3-4** Neoplasm of Appendix: A Retrospective Review of Seven-Year Experience  
Department of surgery, Tribhuvan University Teaching Hospital, Kingdom of Nepal Abhishek Bhattarai
- AOSO-3-5** The Pattern of Colorectal Cancer Care in Indonesia: A Multicenter Study  
Department of Radiation Oncology, Dr. Cipto Mangunkusumo National General Hospital - Faculty of Medicine Universitas Indonesia, Republic of Indonesia Vito Filbert Jayalie

#### AOS Oral Session 4

Thursday, October 19 16:20~17:00

Room18 (301, 3F, Conference Center, Pacifico Yokohama)

#### Prognostic factor in gastric cancer

Chair : Hideo Baba Department of Gastroenterological Surgery,  
Graduate School of Life Sciences, Kumamoto University

- AOSO-4-1** Clinical significance of tissue KLRG2 expression in patients with gastric cancer  
Department of Gastroenterological Surgery,  
Nagoya University Graduate School of Medicine Yuki Ito
- AOSO-4-2** Clinicopathologic relevance of HER-2 oncogene status in gastric cancer patients with curative-intent gastrectomy  
Division of Gastroenterologic Surgery, Department of Surgery, Republic of Korea  
Ho Gun Kim
- AOSO-4-3** Integrin- $\beta 6$  serves as a potential prognostic serum biomarker for gastric cancer  
The Affiliated Hospital of Qingdao University, People's Republic of China  
Zequn Li
- AOSO-4-4** Identification of potential gastric cancer cachexia patients based on gut microbiota  
Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, People's Republic of China Jian Wu

**AOS Oral Session 5**

Thursday, October 19 8:50~9:50

Room19 (302, 3F, Conference Center, Pacifico Yokohama)

**Prognostic factor in colorectal cancer**Chair : Eiji Oki Surgery and Science, Graduate School of Medical Sciences,  
Kyushu University

- AOSO-5-1** Artificial intelligence-based prediction of recurrence after curative resection for colorectal cancer from digital pathological image  
Department of Surgery and Science, Kyushu University Ryota Nakanishi
- AOSO-5-2** The combination of necroptosis associated co-expression networks and molecular typing defines a risk stratification protocol for predicting colorectal cancer prognosis  
Department of Colorectal Cancer Surgery, Tianjin Medical University Cancer Institute and Hospital, People's Republic of China Jun Hu
- AOSO-5-3** The advanced lung cancer inflammation index is a novel independent prognostic factor for colorectal cancer patients  
Department of Gastroenterological Surgery, Kumamoto University Taichi Horino
- AOSO-5-4** Inhibition of neutrophil elastase decreases the liver metastases through the suppression of neutrophil extracellular traps  
Department of Surgery, Uji-Tokushukai Medical Center Rei Mizuno
- AOSO-5-5** Impact of malnutrition on cancer recurrence, colorectal cancer-specific death, and non-colorectal cancer-related death in patients with colorectal cancer who underwent curative surgery  
Department of Surgery, Himeji Medical Center Yuya Nakamura
- AOSO-5-6** Uncovering the oncogenic role of DKK1 in colorectal cancer progression  
National Institute of Cancer Research, National Health Research Institutes, Taiwan Chi-Che Hsieh

**AOS Oral Session 6**

Thursday, October 19 13:35~14:35

Room19 (302, 3F, Conference Center, Pacifico Yokohama)

**Case series of colorectal cancer**

Chair : Gloria R. Cristal-Luna Medical Oncology, Cancer Institute,  
St. Luke's Medical Center,  
Republic of the Philippines

- AOSO-6-1** The Prognostic Significance of Chromosome 18 Monosomy in The Colon Cancer: Correlations with The Expressions of Smad4 and TGF- $\beta$  Receptor II Proteins  
Department of Surgery, College of Medicine, Chung-Ang University,  
Republic of Korea Hee Ju Sohn
- AOSO-6-2** Efficacy of Glyceryl Trinitrate in reducing cardiac events when given concomitantly with capecitabine for at least 3 months in various tumor types  
Hameed Latif Hospital, Islamic Republic of Pakistan Harris Siddiqi
- AOSO-6-3** Pharmacokinetics of anti-cancer drugs in patients with colorectal cancer and end-stage renal disease  
Department of Clinical Pharmacology & Therapeutics, Kyoto University Hospital  
Shunsaku Nakagawa
- AOSO-6-4** Involvement of several inhibitory immune checkpoint ligands in anti-PD-1 antibody therapy-resistant cases with malignant melanoma  
Department of Gastrointestinal Tract Surgery, School of Medicine  
Fukushima Medical University Misato Ito
- AOSO-6-5** Pembrolizumab therapy for unresectable microsatellite instability-high colorectal cancer  
Department of Gastroenterological Surgery, Osaka University School of Medicine  
Tsuyoshi Hata
- AOSO-6-6** Capmatinib in the treatment of metastatic colon cancer patient with Met amplification: A case report  
Division of Oncology, Department of Internal Medicine, Ramathibodi Hospital,  
Mahidol University, Kingdom of Thailand Thun Leewiboonsilp

**AOS Oral Session 7**

Thursday, October 19 15:25~16:15

Room19 (302, 3F, Conference Center, Pacifico Yokohama)

**Basic Research of Head and Neck Cancer/Brain Tumor/Oral Cancer  
1****Chair : Wenbin Li** Department of Neuro-oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, People's Republic of China**AOSO-7-1 Oral Tyrosine Kinase Inhibitors in the Treatment of Chordoma: A Meta-Analysis Based on Nine Single-Arm Trials**

Department of Cancer Center, Beijing Tiantan Hospital, Capital Medical University, People's Republic of China Yi Lin

**AOSO-7-2 Patient-derived orthotopic xenografts of head and neck cancer as a promising platform for personalized cancer treatment**

Peter MacCallum Cancer Center, Australia/Sir Peter MacCallum Department of Oncology, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Australia Yuchen Bai

**AOSO-7-3 OH2 oncolytic viral therapy has a powerful antitumor effect in glioblastoma**

Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, People's Republic of China Yi Zheng

**AOSO-7-4 Dysregulated 7-/24-dehydrocholesterol reductase (DHCR7/24) in cholesterol biosynthesis pathway from Korean patients with head and neck squamous cell carcinoma (HNSCC)**

George Washington University, United States of America Jiyoung Lee

**AOSO-7-5 THERAPEUTIC VULNERABILITY AND RESISTANCE DURING PROGRESSION OF AN AGGRESSIVE SOLITARY FIBROUS TUMOUR**

National Cancer Centre Singapore, Republic of Singapore Valerie Yang

**AOS Oral Session 8**

Thursday, October 19 16:20~17:20

Room19 (302, 3F, Conference Center, Pacifico Yokohama)

**Clinical Experience of Head and Neck Cancer/Brain Tumor/Oral Cancer 1**

Chair : Akihiro Homma Department of Otolaryngology – Head & Neck Surgery,  
Faculty of Medicine and Graduate School of Medicine,  
Hokkaido University

**AOSO-8-1** Outcomes with induction low-dose immunotherapy and chemotherapy for locally advanced inoperable non-metastatic HNSCC.

Department of Medical Oncology, Christian Medical College, Republic of India  
Divya Bala Thumaty

**AOSO-8-2** SYHA1813 in recurrent meningiomas: a case report

Department of Neuro-oncology, Cancer Center, Beijing Tiantan Hospital, Capital  
Medical University, People's Republic of China Wenbin Li

**AOSO-8-3** Survival outcome of the patients who did not have tumor surgery for advanced but resectable oral squamous cell carcinoma

Department of Dentistry and Oral Surgery, Shinshu University School of Medicine  
Hironori Sakai

**AOSO-8-4** Prognosis of patients with lymphopenia who undergo postoperative chemoradiotherapy for glioblastoma

Department of radiation oncology, Hokkaido University Hospital  
Shuhei Takahashi

**AOSO-8-5** Early experience of palliative stereotactic radiotherapy for previously untreated head and neck cancer

Department of Radiation Oncology and Image-Applied Therapy,  
Graduate School of Medicine, Kyoto University Shinya Hiraoka

**AOSO-8-6** Clinical response and treatment outcome in High Risk DLBCL treated with Rituximab based therapy in a tertiary cancer center in Nepal

Nepal Cancer Hospital and Research Center, Kingdom of Nepal  
Sajin Rajbhandary

**AOS Oral Session 9**

Thursday, October 19 8:40~9:40

Room20 (Pearl, 1F, InterContinental Yokohama Grand)

**Advances in Therapy for lung cancer**

Chair : Katsuhiko Naoki Department of Respiratory Medicine,  
Kitasato University School of Medicine

**AOSO-9-1** Withdrawn

- AOSO-9-2** Retrospective study of association between TTF-1 expression and antitumor effects of platinum, pemetrexed and immune checkpoint inhibitor combination therapy for lung adenocarcinoma  
Department of Pulmonary Medicine and Oncology, Graduate School of Medicine,  
Nippon Medical School Sae Takashima
- AOSO-9-3** The efficacy and safety of pembrolizumab plus chemotherapy in Vietnamese patients with stage IV non-small-cell lung cancer  
Hanoi Medical University, Socialist Republic of Viet Nam Lanh Minh Pham
- AOSO-9-4** A retrospective study of the efficacy and safety of nivolumab plus ipilimumab treatment for malignant pleural mesothelioma  
Department of Pulmonary Medicine and Oncology, Graduate School of Medicine,  
Nippon Medical School Hiroki Iida
- AOSO-9-5** Outcomes, response, and prognostic analysis of intrathecal combined treatment for leptomeningeal metastasis from lung adenocarcinoma  
Department of Neuro-oncology, Cancer Center, Beijing Tiantan Hospital,  
Capital Medical University, People's Republic of China Wenbin Li
- AOSO-9-6** Safety and efficacy of stereotactic body radiotherapy for centrally located non-small cell lung cancer  
Department of Radiation Oncology and Image-Applied Therapy, Graduate School of  
Medicine, Kyoto University Masahiro Yoneyama

## AOS Oral Session 10

Thursday, October 19 13:25~14:25

Room20 (Pearl, 1F, InterContinental Yokohama Grand)

### Elderly patient treatment and palliative care for gastric cancer

Chair : Kosaku Mimura Department of Gastrointestinal Tract Surgery,  
Fukushima Medical University School of Medicine

- AOSO-10-1** Short-term outcomes of esophagectomy for elderly patients  
Department of Gastrointestinal Tract Surgery, School of Medicine,  
Fukushima Medical University Akinao Kaneta
- AOSO-10-2** The significance of geriatric nutritional risk index as a prognostic factor for early gastric cancer in elderly patients after non-curative endoscopic resection  
Division of Gastrointestinal Surgery, Department of Surgery,  
Graduate School of Medicine, Kobe University Hitoshi Harada



- AOSO-10-3** Impact of type of gastrectomy on death from pneumonia in very elderly patients with gastric cancer  
Department of Gastroenterological Surgery, Graduate School of Medical Sciences,  
Kumamoto University Takuya Tajiri
- AOSO-10-4** Development and validation of nomograms for predicting overall survival and cancer-specific survival in elderly patients with locally advanced gastric cancer: a population-based study  
The Affiliated Hospital of Qingdao University, People's Republic of China  
Yuqi Sun
- AOSO-10-5** Risk factors of postoperative complications in elderly patients who underwent gastrectomy for gastric cancer  
Department of Gastroenterological and Pediatric Surgery,  
Gifu University Graduate School of Medicine Hiroshi Tsuchiya
- AOSO-10-6** Hemostatic palliative radiotherapy for gastric cancer: A literature review  
Asahi University Hospital, Department of Radiation Oncology Osamu Tanaka

## AOS Oral Session 11

Thursday, October 19 14:35~15:45

Room20 (Pearl, 1F, InterContinental Yokohama Grand)

### Basic research for esophageal cancer

Chair : Ekaphop Sirachainan Ramathibodi Comprehensive Cancer Center,  
Faculty of Medicine, Ramathibodi hospital,  
Mahidol University, Kingdom of Thailand

- AOSO-11-1** STX3 expression and prognosis of patients with esophageal cancer  
Department of Gastroenterological Surgery,  
Nagoya University Graduate School of Medicine Yuki Ito
- AOSO-11-2** CHAF1A promotes the translesion DNA synthesis pathway in response to DNA replication stress  
Department of Biochemistry and Molecular Biology,  
Shantou University Medical College, People's Republic of China Bing Wen
- AOSO-11-3** Withdrawn
- AOSO-11-4** KAT8/SIRT7-mediated Fascin-K41 acetylation/deacetylation regulates tumor metastasis  
The Key Laboratory of Molecular Biology for High Cancer Incidence Coastal  
Chaoshan Area, Department of Biochemistry and Molecular Biology,  
Shantou University Medical College, People's Republic of China/Guangdong  
Provincial Key Laboratory of Infectious Diseases and Molecular Immunopathology,  
Institute of Oncologic Pathology, Cancer Research Center,  
Shantou University Medical College, People's Republic of China Da-Jia Li

**AOSO-11-5** The effect of IL-34 triggered by neoadjuvant chemotherapy on the tumor-microenvironment and clinical outcomes in patients with esophageal squamous cell carcinoma

Department of Multidisciplinary Treatment of Cancer and Regional Medical Support,  
Fukushima Medical University School of Medicine/Department of Gastrointestinal  
Tract Surgery, Fukushima Medical University School of Medicine  
Shotaro Nakajima

**AOSO-11-6** Frequency of exhausted T cells after chemotherapy or chemoradiotherapy in patients with esophageal squamous cell carcinoma

Department of Gastrointestinal Tract Surgery,  
Fukushima Medical University School of Medicine Mei Sakuma

**AOSO-11-7** Genomic Profiling of Taiwanese Esophageal Squamous Cell Carcinoma -the Interim Report of the Registry Study of Genetic Alterations of Esophageal Cancer in Taiwan (T4221 Trial)

National Institute of Cancer Research, National Health Research Institutes, Taiwan/  
Department of Oncology, National Cheng Kung University Hospital, College of  
Medicine, National Cheng Kung University, Taiwan Shang-Hung Chen

## AOS Oral Session 12

Thursday, October 19 16:00~17:20

Room20 (Pearl, 1F, InterContinental Yokohama Grand)

### Treatment for gastric cancer

Chair : Toshiyoshi Fujiwara Department of Gastroenterological Surgery, Faculty of Medicine,  
Dentistry and Pharmaceutical Sciences, Okayama University

**AOSO-12-1** Treatment strategy of repeated intraperitoneal administration of paclitaxel combined with S-1 plus cisplatin for gastric cancer with peritoneal metastasis

Department of Gastroenterological Surgery, Komaki City Hospital/Department of  
Gastroenterological Surgery, Nagoya University Graduate School of Medicine  
Daisuke Kobayashi

**AOSO-12-2** PATHOLOGICAL RESPONSE IN PATIENTS RECEIVING FLOT (5 FU, LEUCOVORIN, OXALIPLATIN, AND DO-CETAXEL) REGIMEN IN THE NEOADJUVANT SETTING FOR ESOPHAGOGASTRIC AND GASTRIC CANCER

Department of Medical Oncology, Aga Khan University Hospital,  
Islamic Republic of Pakistan Tasneem Dawood

**AOSO-12-3** Withdrawn

**AOSO-12-4** Bemarituzumab (bema) for treatment of previously untreated advanced and/or metastatic gastric and gastroesophageal cancer (GC): Final analysis of a randomized phase 2 trial (FIGHT)

Gastroenterological Chemotherapy Department,  
The Cancer Institute Hospital of JFCR Kensei Yamaguchi

**AOSO-12-5** Phase I/II clinical trial of repeated intraperitoneal administration of GAIA-102 in patients with microsatellite stable (MSS) advanced gastric/pancreatic cancer with malignant ascites

Department of Surgery and Science, Graduate School of Medical Sciences,  
Kyushu University Mitsuhiko Ota

**AOSO-12-6** Lymph node metastasis in mucosal gastric cancer within newly added absolute indication for ESD

Department of Surgery, Seoul National University Hospital, Republic of Korea  
Chungyoon Kim

**AOSO-12-7** Withdrawn

**AOSO-12-8** Short-term outcomes of laparoscopic gastrectomy for gastric cancer in clinically advanced stage

Department of Clinical Anatomy Development Studies,  
Gifu University Graduate School of Medicine Itaru Yasufuku

## AOS Oral Session 13

Friday, October 20 13:55~14:55

Room17 (311+312, 3F, Conference Center, Pacifico Yokohama)

### Pancreatic carcinoma: Clinical

Chair : Itaru Endo Department of Gastroenterological Surgery,  
Yokohama City University Graduate School of Medicine

**AOSO-13-1** Withdrawn

**AOSO-13-2** GATA6 and CK5 stratify the survival of patients with pancreatic cancer undergoing neoadjuvant chemotherapy

Department of Surgery, Tohoku University Graduate School of Medicine  
Takashi Kokumai

**AOSO-13-3** Feasibility of laparoscopic versus open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer

Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center,  
People's Republic of China Zheng Li

**AOSO-13-4** Safety and prognosis of pancreaticoduodenectomy in older adults over age 80 with pancreatic cancer

Department of Gastroenterological Surgery, Graduate School of Medicine,  
Gifu University Katsutoshi Murase

**AOSO-13-5** Prognostic Impact of Reticular Pattern around Superior Mesenteric Artery in CT Images of Pancreatic Cancer

Department of Hepatobiliary and Pancreatic Surgery,  
Tokyo Medical and Dental University Akira Ito

**AOSO-13-6** Preoperative sarcopenia assessment predicts loss of independence after Pancreaticoduodenectomy (PD) in pancreatic cancer patients

Department of Hepatobiliary and Pancreatic Surgery,  
Tokyo Medical and Dental University Atsushi Nara

## AOS Oral Session 14

Friday, October 20 15:00~16:00

Room17 (311+312, 3F, Conference Center, Pacifico Yokohama)

### HPB malignancy: others

Chair : Hidetoshi Eguchi Department of Gastroenterological Surgery,  
Graduate School of Medicine, Osaka University

**AOSO-14-1** The Prognostic Significance of GATA6 and CD133/CD44 Expression, and Germline Homologous Recombination Gene Mutation in Metastatic Pancreatic Ductal Adenocarcinoma

National Health Research Institutes, Taiwan/National Cheng Kung University  
Hospital, Taiwan/Kaohsiung Medical University, Taiwan Yung-Yeh Su

**AOSO-14-2** The rapid diagnosis of liver tumors using mass spectrometry and machine learning

Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery,  
Graduate School of Medicine, The University of Tokyo Hiroyuki Hakoda

**AOSO-14-3** Treatment outcome of neoadjuvant chemoradiotherapy for resectable pancreatic cancer

Department of Gastroenterological Surgery, Graduate School of Medicine,  
Osaka University Yoshito Tomimaru

**AOSO-14-4** Impact of transduodenal ampullectomy for early ampullary cancer

Department of Gastroenterological Surgery, Saitama Cancer Center  
Ryoichi Miyamoto

**AOSO-14-5** Determining the Indication of Surgery for High grade pNENs

Department of HBP surgery, Tokyo Medical and Dental University Shotaro Gan

**AOSO-14-6** Prognostic stratification provided by lymphovascular invasion of pancreatic neuroendocrine neoplasms

Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School  
of Medicine, The University of Tokyo Sho Kiritani

**AOS Oral Session 15**

Friday, October 20 16:10~17:20

Room17 (311+312, 3F, Conference Center, Pacifico Yokohama)

**Hepatocellular carcinoma: Clinical**

Chair : Manabu Kawai Second Department of Surgery, Wakayama Medical University

**AOSO-15-1 Low dose nivolumab with TKI in advanced HCC: Real world outcomes from India**Department of Medical Oncology, Christian Medical College, Republic of India  
Jerryes Pious Wisely**AOSO-15-2 Lenvatinib exposure relationship with clinical efficacy, toxicity, and gene polymorphisms in the treatment of advanced hepatocellular carcinoma in the observational retrospective study**

College of Pharmaceutical Sciences, Ritsumeikan University Satoshi Noda

**AOSO-15-3 TIPE3 is a candidate prognostic biomarker promoting tumor progression via elevating RAC1 in pancreatic cancer**The Affiliated Hospital of Qingdao University, People's Republic of China  
Zequn Li**AOSO-15-4 Efficacy of liver-directed combined radiotherapy in locally advanced hepatocellular carcinoma with portal vein tumor thrombosis**Department of Radiation Oncology, Yonsei Cancer Center,  
Yonsei University College of Medicine, Republic of Korea Jina Kim**AOSO-15-5 Clinical outcomes of Carbon-ion radiotherapy for large-sized ( $\geq 4\text{cm}$ ) hepatocellular carcinoma**QST Hospital, National Institute for Quantum Science and Technology  
Masaru Wakatsuki**AOSO-15-6 Proton beam therapy for HCC exceeding "up-to-seven" criteria**Department of Radiation Oncology and Proton Medical Research Center,  
Faculty of Medicine, University of Tsukuba Hirokazu Makishima**AOSO-15-7 Surgical outcomes of hepatectomy for liver cancers derived from congestive liver disease**Department of Gastroenterological Surgery, Graduate School of Medicine,  
Osaka University Takehiro Noda

**AOS Oral Session 16**

Friday, October 20 17:30~18:20

Room17 (311+312, 3F, Conference Center, Pacifico Yokohama)

**Primary and metastatic liver carcinoma**

Chair : 変更予定 変更予定

**AOSO-16-1** RNF31 promotes proliferation and invasion of hepatocellular carcinoma via nuclear factor kappaB activationDepartment of General Surgical Science,  
Gunma University Graduate School of Medicine Kouki Hoshino**AOSO-16-2** Diagnostic Performance of the 2018 EASL Versus LI-RADS for Hepatocellular Carcinoma Using CT and MRI: A Systematic Review and Meta-Analysis of Comparative StudiesDepartment of Radiology, Severance Hospital, Yonsei University College of Medicine,  
Republic of Korea Sunyoung Lee**AOSO-16-3** Imaging evaluation of colorectal liver metastases after chemotherapy

Department of Surgery, National Defense Medical College Yuka Noguchi

**AOSO-16-4** Surgical management of borderline resectable colorectal liver metastases: vessel-skeletonized parenchyma-sparing hepatectomy (VESPAH)

Department of Gastroenterological Surgery, Okayama University Yuzo Umeda

**AOSO-16-5** Posthepatectomy but not prehepatectomy chemotherapy prolongs the time to recurrence after resection of resectable colorectal liver metastases: Inverse probability of treatment weighting analysisHepato-Biliary-Pancreatic Surgery Division, Department of Surgery,  
Graduate School of Medicine, the University of Tokyo Yuhi Yoshizaki**AOS Oral Session 17**

Friday, October 20 8:50~10:00

Room19 (302, 3F, Conference Center, Pacifico Yokohama)

**Proton beam, high-precision EBRT, biology**

Chair : Hitoshi Ishikawa National Institutes for Quantum Science and Technology

**AOSO-17-1** The outcomes and prognostic factors of neoadjuvant chemoradiotherapy using intensity-modulated radiotherapy for borderline resectable pancreatic cancerDepartment of Radiation Oncology and Image-Applied Therapy,  
Graduate School of Medicine, Kyoto University Takahiro Iwai

**AOSO-17-2** New stereotactic body radiation therapy method combining two respiratory motion managements: Deep inspiration breath hold real-time tumor-tracking radiation therapy (DIRT)

Department of Radiation Oncology,  
Yamaguchi University Graduate School of Medicine Hidekazu Tanaka

**AOSO-17-3** Withdrawn

**AOSO-17-4** Withdrawn

**AOSO-17-5** Synergistic effect of high dose irradiation with EC-18 on the downregulation of PD-L1 expression in FSall fibrosarcoma

Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences,  
Republic of Korea/Department of Radiological & Medico-Oncological Science,  
University of Science and Technology, Republic of Korea Haeun Cho

**AOSO-17-6** Long-term outcomes of proton beam therapy for elderly patients with prostate cancer

Department of Radiation Oncology and Proton Medical Research Centre,  
Faculty of Medicine, University of Tsukuba Toshiki Ishida

**AOSO-17-7** Cost-effectiveness analysis of proton beam therapy for locally advanced unresectable pancreatic cancer

Radiation Oncology & Proton Medical Research Center, Faculty of Medicine,  
University of Tsukuba/Department of Radiation Oncology,  
Ibaraki Prefectural Central Hospital Yuichi Hiroshima

## AOS Oral Session 18

Friday, October 20 10:15~11:15

Room19 (302, 3F, Conference Center, Pacifico Yokohama)

### Physics, brachytherapy, Breast, others

Chair : Takashi Uno Diagnostic Radiology and Radiation Oncology,  
Graduate School of Medicine, Chiba University

**AOSO-18-1** Implementation of MRgOART workflow for pancreatic cancer patients; Inter-observer variability of organs-at-risk

Graduate School of Medicine, Chiba University Masato Tsuneda

**AOSO-18-2** Evaluation of the dose distribution and safety of modified track DWA therapy for accelerated partial breast irradiation

Department of Radiation Oncology and Image-applied Therapy  
Kyoto University Graduate School of Medicine Yuka Ono

- AOSO-18-3** Comprehensive Hypofractionated Radiotherapy for Refractory or Relapsed Aggressive B-cell Lymphoma in the Rituximab Era  
Department of Radiation Oncology, Fujian Medical University Union Hospital,  
People's Republic of China Cheng Huang
- AOSO-18-4** Hydrogel spacer within the perirectal space in radiotherapy for prostate cancer: Anatomical distribution, rectal/urethral dose and influence of experience  
Department of Radiology, Keio University School of Medicine/  
Department of Radiation Oncology, National Hospital Organization  
Tokyo Medical Center Hirofumi Toyama
- AOSO-18-5** Optimal combination of cyclophosphamide and SABR to increase antitumor immunity  
Department of Radiation Oncology, Korea Institute of Radiological & Medical  
Sciences, Republic of Korea Hyunkyung Kim
- AOSO-18-6** Three-dimensional image-guided adaptive brachytherapy in cervical cancer patients  
Department of Radiology, Kurume University School of Medicine  
Yusaku Miyata

## AOS Oral Session 19

Friday, October 20 11:25~12:25

Room19 (302, 3F, Conference Center, Pacifico Yokohama)

### Novel diagnostic/therapeutic approach for gynecological cancers

Chair : Masaki Mandai Department of Gynecology and Obstetrics,  
Graduate School of Medicine, Kyoto University

- AOSO-19-1** Identification of prognostic factors that indicate the possible individualization of surgical procedures in early-stage ovarian cancer  
Department of Gynecology and Obstetrics,  
Kyoto University Graduate School of Medicine Ken Yamaguchi
- AOSO-19-2** Preoperative CECT-based multitask model predicts peritoneal recurrence and DFS in advanced ovarian cancer: a multicenter study  
School of Biomedical Engineering & Technology, Tianjin Medical University, People's  
Republic of China/Department of Breast Imaging, Tianjin Medical University Cancer  
Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory  
of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer,  
People's Republic of China Rui Yin



- AOSO-19-3** Outcomes of ovarian cancer patients with HRD/BRCA gene alterations treated with PARP inhibitors (PARPi) at a cancer care center of a tertiary hospital in eastern India  
Department of Medical Oncology, IMS and SUM Hospital, Bhubaneswar, Odisha, Republic of India Susheel Kumar Yeshala
- AOSO-19-4** Defining Models to Differentiate Epithelial Ovarian Cancer from Benign Ovarian Mass Using Routine Laboratory Parameters  
Department of Internal Medicine, College of Medicine, Kyung Hee University, Republic of Korea/Department of Obstetrics and Gynecology, Pusan National University School of Medicine, Republic of Korea/Department of Nursing, Dongyang University, Republic of Korea/College of Nursing Science, Kyung Hee University, Republic of Korea Wankyueo
- AOSO-19-5** The potential of fertility enhancement through the cryopreservation of in vitro-matured oocytes in addition to ovarian tissue cryopreservation for pediatric patients  
St. Marianna University Kaoru Ito
- AOSO-19-6** Development of the artificial ovary to reduce the risk of reimplantation of minimal residual disease in ovarian tissue transplantation  
Department of Obstetrics and Gynecology, St. Marianna University School of Medicine Hideyuki Iwahata

## AOS Oral Session 20

Friday, October 20 13:55~15:05

Room19 (302, 3F, Conference Center, Pacifico Yokohama)

### Diagnosis/therapy for cervical cancer

Chair : Nao Suzuki Department of Obstetrics and Gynecology, St. Marianna University School of Medicine

- AOSO-20-1** Fertility-sparing radical trachelectomy for early-stage cervical cancer: First series performed in Viet Nam  
Department of Gynecological Surgery, Oncology Hospital at Ho Chi Minh City, Socialist Republic of Viet Nam/Department of Oncology, University of Medicine and Pharmacy at Ho Chi Minh City, Socialist Republic of Viet Nam Nghia Trong Doan
- AOSO-20-2** Long-term oncologic and obstetric abdominal radical trachelectomy (ART)in a series of 297 cases  
Department of Obstetrics and Gynecology, Keio University School of Medicine Hiroshi Nishio

- AOSO-20-3** Reconstruction of vaginal and pelvic floor defects after pelvic exenteration: Four case reports and literature review  
Department of Gynecology, Ho Chi Minh City Oncology Hospital, Socialist Republic of Viet Nam Bao Viet Viet Phan
- AOSO-20-4** Long-term outcomes of chemo carbon-ion radiotherapy for uterine cervical adenocarcinoma in a phase 1/2 trial  
National Institutes for Quantum and Science and Technology, QST Hospital Kazutoshi Murata
- AOSO-20-5** Pretreatment peripheral hematological markers in patients with cervical cancer treated with concurrent chemoradiotherapy  
Department of Gynecology Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, People's Republic of China Wei Mao
- AOSO-20-6** Safety and efficacy of imiquimod for cervical and vaginal intraepithelial neoplasia: A systematic review and meta-analysis  
Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine/Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University Yoshihide Inayama
- AOSO-20-7** A comprehensive gene mutation profiling of ctDNA-liquid biopsy from cervical cancer patients by using CAPP-seq  
Department of Obstetrics and Gynecology, School of Medicine, Wakayama Medical University Naoyuki Iwahashi

## AOS Oral Session 21

Friday, October 20 15:15~16:15

Room19 (302, 3F, Conference Center, Pacifico Yokohama)

### Diagnosis and treatment for rare tumors in gynecology

Chair : Elaine Hsuen Lim National Cancer Centre Singapore, Republic of Singapore

- AOSO-21-1** Vulvar Rhabdomyosarcoma in an Adult Female Patient, A case report and review of literature  
Division of Medical Oncology, Department of Medicine, University of the Philippines-Philippine General Hospital (UP-PGH), Republic of the Philippines Carl Lawrence Calaunan Arenos
- AOSO-21-2** Proximal-Type Epithelioid Sarcoma of the Vulva: A Case Report  
Department of Laboratories, Philippine General Hospital, Republic of the Philippines Pauline Mae R. Dy

**AOSO-21-3** HIF2A showed a poor prognostic factor and a possible therapeutic target in ovarian clear cell carcinoma  
 Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine Mengxin Jiang

**AOSO-21-4** Withdrawn

**AOSO-21-5** Two cases of ovarian mucinous carcinoma deriving from mucinous borderline tumors with fatal outcomes  
 Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine Mana Taki

**AOSO-21-6** Clinicopathological characteristics and oncological outcomes of three subtypes of neuroendocrine carcinoma of the cervix: a multicenter retrospective study of 288 patients in China  
 Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, People's Republic of China Yu Gu

## AOS Oral Session 22

Friday, October 20 16:30~17:30

Room19 (302, 3F, Conference Center, Pacifico Yokohama)

### CNS, sarcoma in radiation oncology

Chair : Endang Nuryadi Department of Radiation Oncology, Dr. Cipto Mangunkusumo National General Hospital, Republic of Indonesia

**AOSO-22-1** Addition of local treatment for extracranial metastases prolongs survival in patients with brain metastases from non-small cell lung cancer  
 Department of Radiotherapy, Cancer Hospital of China Medical University, People's Republic of China Yu Wu

**AOSO-22-2** Lineac-based volumetric modulated arc therapy cranio-spinal irradiation  
 Department of Radiology, Keio University School of Medicine Junichi Fukada

**AOSO-22-3** Stereotactic Radiosurgery in the Treatment of Tremor: A Systematic Review  
 Department of Radiation Oncology, Dr. Cipto Mangunkusumo National General Hospital, Faculty of Medicine Universitas Indonesia, Republic of Indonesia Endang Nuryadi

**AOSO-22-4** Modified Hot Dog Technique for Epiphyseal Sparing Primary Malignant Bone Sarcomas of Femur; Reconstruction with composite of Recycled Tumor Bone with ECRT and Vascularized fibula  
 Department of Orthopedic Oncology, Bhagwan Mahaveer Cancer Hospital & Research Center, Republic of India Praveen Gupta

**AOSO-22-5** Comparison of a treatment strategy for myxofibrosarcoma among Asian countries -Preliminary survey for a multicenter collaborative study-

Department of Musculoskeletal Oncology and Rehabilitation,  
National Cancer Center Hospital Shintaro Iwata

**AOSO-22-6** Palliative Radiotherapy on Multiple Metastatic Lesion of Wilms Tumour: A Case Report

Department of Radiation Oncology, Faculty of Medicine Universitas Indonesia, Cipto  
Mangunkusumo General Hospital, Republic of Indonesia Putri Maharani

### AOS Oral Session 23

Friday, October 20 17:45~18:45

Room19 (302, 3F, Conference Center, Pacifico Yokohama)

#### Prostate cancer

Chair : Hiroji Uemura Yokohama City University Medical Center,  
Department of Urology and Renal Transplantation

**AOSO-23-1** The need for sanitary box placement as revealed by incontinence pad management after radical prostatectomy

Department of Urology, Showa University School of Medicine Yoshiko Maeda

**AOSO-23-2** Elucidating Key Genetic Determinants of PARP Inhibitor Sensitivity in Prostate Cancer through Genome-wide CRISPR-Cas9 Screening

Department of Urology, Osaka Medical and Pharmaceutical University  
Takuya Tsujino

**AOSO-23-3** Heterogeneity of [68Ga]Ga - PSMA - 11 PET/CT in metastatic castration - resistant prostate cancer: genomic characteristics and association with abiraterone/enzalutamide response

Fudan University Shanghai Cancer Center, People's Republic of China Jian Pan

**AOSO-23-4** Cross-resistance between cabazitaxel and new androgenic agent in patients with metastatic castration-resistant prostate cancer

Tokyo Medical University Takeshi Hashimoto

**AOSO-23-5** The efficacy of geriatric nutritional risk index as a prognostic marker for up-front abiraterone plus androgen deprivation therapy for Japanese patients with LATITUDE high-risk prostate cancer

Department of Nephro-urology, Nagoya City University  
Graduate School of Medical Sciences Taku Naiki

**AOSO-23-6** Is neutropenia associated with the extent of bone metastases in Docetaxel treatment for castration-resistant prostate cancer?

Department of Urology, Showa University School of Medicine  
Yoshihiro Nakagami

## AOS Oral Session 24

Friday, October 20 8:30~9:30

Room20 (Pearl, 1F, InterContinental Yokohama Grand)

### Utility tools for screening and prognosis of breast cancer

Chair : Yogendra P. Singh Surgical Oncology, Department of Surgery  
Tribhuvan University Teaching Hospital Kathmandu,  
Kingdom of Nepal

**AOSO-24-1** Addressing Equity Diversity and Inclusion in Screening and Early Detection of Breast Cancer Infrastructure in Pakistan: A Gap analysis Study Based on field Research

Radiological Society of Pakistan, Islamic Republic of Pakistan Naseem Begum

**AOSO-24-2** The relationship between mammographic features and clinicopathological parameters in Chinese data base

Tianjin Medical University Cancer Institute and Hospital, People's Republic of China  
Yacong Liu

**AOSO-24-3** An artificial intelligence diagnosis for breast ultrasound obtained using a smartphone

Department of Breast Surgery, Gifu University Graduate School of Medicine  
Ryutaro Mori

**AOSO-24-4** From the Vietnamese mammography database to an artificial intelligence-based breast cancer diagnostic model: The interim results of a national project

Cancer Research and Clinical Trial Centre, Vietnam National Cancer Hospital, Socialist  
Republic of Viet Nam Dung Khac NGUYEN

**AOSO-24-5** Association of Neoadjuvant versus Adjuvant Chemotherapy with Survival Outcomes among Early and Locally Advanced Breast Cancer Patients at Rizal Medical Center: A 7-year Real World Experience

Department of Internal Medicine, Rizal Medical Center, Republic of the Philippines  
Lavinia Lyka Lim Lopez

**AOSO-24-6** Impact of different surgery types on the unmet need of Chinese breast cancer patients: a propensity score matching-based study

Department of Breast Surgery, Shanxi Bethune Hospital,  
People's Republic of China Yuting Zhang

**AOS Oral Session 25**

Friday, October 20 10:10~11:10

Room20 (Pearl, 1F, InterContinental Yokohama Grand)

**Pathophysiology of breast cancer**

Chair : Takashi Ishikawa Tokyo Medical University

**AOSO-25-1 HER2 expression in breast cancer by proteomics analysis**Targeted Therapy Branch, Research Institute, National Cancer Center,  
Republic of Korea Gi Yeon LEE**AOSO-25-2 Clinicopathological characteristics and Treatment Outcomes of Metaplastic Breast Cancer: A Study at The Vietnam National Cancer Hospital**

Hanoi Medical University, Socialist Republic of Viet Nam Toan Khanh Phan

**AOSO-25-3 An observational study in Microinvasive breast carcinoma at Viet Nam: Patient's characteristics and Outcomes**

K National Hospital, Socialist Republic of Viet Nam Hoan Doan Nguyen

**AOSO-25-4 Survival of metastatic breast cancer patients in resource-limited setting**Department of Medical Oncology Hameed Latif Hospital, Islamic Republic of Pakistan  
Zaigam Ismail**AOSO-25-5 Surface Mould Brachytherapy for Recurrence Breast Cancer: A Case Report**Department of Radiation Oncology, Dr. Cipto Mangunkusumo National General  
Hospital - Faculty of Medicine Universitas Indonesia,  
Republic of Indonesia Endang Nuryadi**AOSO-25-6 Use of Trastuzumab emtansine (T-DM1) within 1-year of stereotactic radiosurgery increases the risk of radionecrosis in HER2 positive breast cancer**Department of Radiation Oncology, Seoul National University Hospital,  
Republic of Korea Seok-Joo Chun**AOS Oral Session 26**

Friday, October 20 11:25~12:25

Room20 (Pearl, 1F, InterContinental Yokohama Grand)

**Clinical aspect of thyroid and breast cancer**Chair : Hiroko Bando University of Tsukuba, Institute of Medicine,  
Breast and Endocrine Surgery**AOSO-26-1 Withdrawn**

- AOSO-26-2** Comparative outcomes of Doxorubicin and Cyclophosphamide with concurrent versus sequential Paclitaxel in the adjuvant treatment of Breast Cancer  
Department of Internal Medicine, Maharajgunj Medical Campus, Kathmandu, Kingdom of Nepal Bishal Paudel
- AOSO-26-3** APPLICATION OF COMPOSITE RISK IN ADJUVANT SETTINGS OF EARLY BREAST CANCER HR+: REAL WORLD DATA AT HO CHI MINH CITY ONCOLOGY HOSPITAL  
Ho Chi Minh City Oncology Hospital, Socialist Republic of Viet Nam  
Tien Hoang Luong
- AOSO-26-4** Treatment choice and related outcomes for elderly breast cancers in Taiwan  
Taipei Veterans General Hospital, Taiwan Chi-Cheng Huang
- AOSO-26-5** Clinical Profiles and Outcomes of Patients enrolled in the Department of Health -Breast Cancer Medicines Access Program: A Single Center Experience  
Division of Internal Medicine, Section of Medical Oncology, National Kidney and Transplant Institute, Republic of the Philippines Jason King Dalusung Talao
- AOSO-26-6** Real world experience with Palbociclib in breast cancer -Patient assistance program comparison  
Mahatma Gandhi Medical College Hospital, MGUMST, Republic of India  
Purvish Mahendra Parikh

## AOS Oral Session 27

Friday, October 20 13:55~14:55

Room20 (Pearl, 1F, InterContinental Yokohama Grand)

### Neoadjuvant chemotherapy for breast cancer

Chair : Takafumi Sangai Department of Breast and Thyroid Surgery  
Kitasato University School of Medicine

- AOSO-27-1** Companion Diagnostics for Trastuzumab-based Neoadjuvant Therapy -Two is better than One  
Cancer Precision Medicine Research Centre, Ningbo Institute of Life and Health Industry Research, University of the Chinese Academy of Sciences, People's Republic of China/Yong Loo Lin School of Medicine, National University of Singapore, Republic of Singapore Yoon Pin Lim
- AOSO-27-2** Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer  
Department of Breast Surgery, Gifu University Hospital Manabu Futamura

**AOSO-27-3** Temporal heterogeneity of HER2 correlates with P53, progesterone receptor and neoadjuvant response of HR +HER2- breast cancer

Department of Breast Pathology and Lab, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, People's Republic of China Xiao-Long Qian

**AOSO-27-4** Prognoses of Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy before Surgery: a Retrospective Analysis

The 3rd Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, People's Republic of China Shichao Zhang

**AOSO-27-5** Effects and clinical significance of tumor-infiltrating lymphocytes on nonresponse rate of neoadjuvant chemotherapy in patients with invasive breast cancer

Department of Breast Pathology and Lab, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, People's Republic of China Xiao-Jing Guo

**AOSO-27-6** Withdrawn**AOS Oral Session 28**

Friday, October 20 15:10~16:10

Room20 (Pearl, 1F, InterContinental Yokohama Grand)

**Basic research for targeted therapy in breast cancer**

Chair : Eriko Tokunaga Department of Breast Oncology, NHO Kyushu Cancer Center

**AOSO-28-1** Development of surface-engineered NK cell with chimeric antigen receptor (CAR) recombinant fusion protein system

Department of Smart Health Science and Technology convergence, College of ACE, Kangwon National University, Republic of Korea Su Yeon Lim

**AOSO-28-2** Multi-drug Targeted Delivery System Using Recombinant Fusion Protein with Drug Specific Binding Domain

Department of Smart Health Science and Technology convergence, College of ACE, Kangwon National University, Republic of Korea Chanho Park

**AOSO-28-3** Development of surface-engineered NK cells using antibody-binding fusion proteins for targeted delivery

Department of Smart Health Science and Technology convergence, College of ACE, Kangwon National University, Republic of Korea Yihyeon Kim



**AOSO-28-4 GRHL2 loss-mediated mesenchymal-like dormancy preventing tumor growth and lung metastasis in basal-like TNBC**

Department of Clinical Laboratory, Tianjin Medical University Cancer Institute and Hospital, People's Republic of China/Leiden Academic Center for Drug Research, Leiden, Leiden University, Kingdom of the Netherlands Zi Wang

**AOSO-28-5 Discovery and development of a new generation of anti-mitotic agents for more effective treatment of drug-resistant cancers**

Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, United States of America Wei Li

**AOSO-28-6 PRAK-GTPBP4-RhoA pathway is activated in tumor angiogenesis and that is targetable by PRAK inhibition**

Tianjin Medical University Cancer Institute and Hospital, People's Republic of China Jin Zhang

**AOS Oral Session 29**

Friday, October 20 16:25~17:15

Room20 (Pearl, 1F, InterContinental Yokohama Grand)

**Breast reconstruction, genetic counselling and RFA**

Chair : Manabu Futamura Department of Breast Surgery, Gifu University Hospital  
Purvish Mahendra Parikh Mahatma Gandhi Medical College Hospital, MGUMST

**AOSO-29-1 Analysis of immediate breast reconstruction after nipple-sparing mastectomy in 610 cases**

Department of Breast Oncoplastic Surgery, Tianjin Medical University Cancer Institute & Hospital, People's Republic of China Jie Wang

**AOSO-29-2 Current status and influencing factors of participating satisfaction during surgical treatment decision-making among breast cancer patients with immediate breast reconstruction**

Tianjin Medical University Cancer Institute and Hospital, People's Republic of China Yan Wang

**AOSO-29-3 DIRECT-TO-IMPLANT BREAST RECONSTRUCTION IN EARLY-STAGE BREAST CANCER UTILIZING AUTOLOGOUS DERMAL GRAFT**

Department of Breast Surgery, Oncology Hospital at Ho Chi Minh City, Socialist Republic of Viet Nam An CH Tran

**AOSO-29-4 Comparison of Pedigree Generating Programs for Genetic Counselling of Hereditary Cancer**

Targeted Therapy Branch, Research Institute, National Cancer Center, Republic of Korea Ye-Ryeong Jung

**AOSO-29-5** Phase II study on radiofrequency ablation in stage 0 and I breast cancer without extensive intraductal components

Department of Breast Surgery, Kyorin University Hospital Shigeru Imoto

### **AOS Oral Session 30**

Friday, October 20 17:30~18:20

Room20 (Pearl, 1F, InterContinental Yokohama Grand)

#### **Translational research for breast cancer**

Chair : Tetsu Hayashida Department of Surgery, Keio University School of Medicine

**AOSO-30-1** Metabolomics Approach for Exploring Potential Biomarkers Associated with Treatment Response of Neoadjuvant Therapy in HER2+ Breast Cancer

Department of Breast Cancer Center, Chongqing University Cancer Hospital,  
People's Republic of China Ningning Zhang

**AOSO-30-2** Role of cell free DNA and DNA integrity index in assessing the response to neoadjuvant chemotherapy in patients with carcinoma breast -a prospective study

Regional Cancer Centre, Trivandrum, Republic of India Bhavya S Kumar

**AOSO-30-3** Establishment of an orthotopically transplanted mouse model of patient-derived organoids~aiming to elucidate the pathogenesis of metastatic breast cancer~

Project For Cancer Epigenomics, Cancer Institute, Japanese Foundation For Cancer  
Research Ai Tsuchiya

**AOSO-30-4** Inhibition of ATM promotes PD-L1 expression by activating JNK/c-Jun/TNF-alpha signaling pathway in triple-negative breast cancer

Department of Breast Pathology and Lab, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, People's Republic of China Xiao-Jing Guo

**AOSO-30-5** PIK3CA mutations in hormone positive Her2 negative early breast cancer: Experience from a tertiary care center in Eastern India

Department of Medical Oncology, Institute of Medical Sciences and Sum Hospital,  
Siksha 'O' Anusandhan University, Republic of India Soumya Surath Panda

**AOS Oral Session 31**

Saturday, October 21 8:30~9:30

Room17 (311+312, 3F, Conference Center, Pacifico Yokohama)

**Urothelial cancer biomarker. Diagnosis**

Chair : Agus Rizal Ardy Hariandy Hamid Department of Urology,  
Faculty of Medicine, Universitas Indonesia,  
Republic of Indonesia

**AOSO-31-1** Identification and visualization of the spatio-temporal  
distribution of phosphatidic acids in bladder cancer  
Department of Urology, Faculty of Medicine, University of Tsukuba  
Kazuki Hamada

**AOSO-31-2** The Efficacy of Red Channel Enhanced Images and Di-  
lated Convolution for AI Segmentation of Bladder Tu-  
mors in Cystoscopic Images  
Department of Urology, Kyushu University Hospital Jun Mutaguchi

**AOSO-31-3** Gene analysis of normal urothelium and tumor of  
patients with non-muscle invasive bladder cancer  
Department of Urology, Kindai University Kazutoshi Fujita

**AOSO-31-4** A case of urothelial carcinoma with trophoblastic differ-  
entiation in renal pelvis with high tumor mutation  
burden successfully treated with pembrolizumab  
Department of Urology, Keio University School of Medicine Sotaro Kitaoka

**AOSO-31-5** Potential role of Vasohibin-1 in the prediction of patho-  
logical response after neoadjuvant chemotherapy  
Department of Urology, Kawasaki Municipal Kawasaki Hospital  
Minami Omura

**AOSO-31-6** A multi-omics analysis revealed NECTIN4 as a potential  
predictive marker of precision therapy in bladder cancer  
Division of Cancer RNA Research, National Cancer Center Research Institution/  
Department of Urology, Osaka Medical and Pharmaceutical University  
Kazuki Nishimura

**AOS Oral Session 32**

Saturday, October 21 9:40~10:40

Room17 (311+312, 3F, Conference Center, Pacifico Yokohama)

**Urothelial cancer treatment**

Chair : Eiji Kikuchi Department of Urology, St. Marianna University School of Medicine

**AOSO-32-1** Comparative effects of radical cystectomy versus radia-  
tion in localized muscle-invasive bladder cancer  
Department of Urology, Osaka University Graduate School of Medicine/  
Cancer Control Center, Osaka International Cancer Institute  
Yoshiyuki Yamamoto

**AOSO-32-2** Concurrent Palliative Radiation Could Prolong Overall Survival in Patients Treated with Pembrolizumab for Platinum-Refractory Urothelial Carcinoma  
Department of Urology, Osaka Medical and Pharmaceutical University  
Shogo Yamazaki

**AOSO-32-3** A new risk stratification for adjuvant nivolumab following radical surgery of high-risk muscle-invasive urothelial carcinoma  
Department of Uro-Oncology, Saitama Medical University International Medicine Center/Department of Urology, Keio University School of Medicine/Department of Urology, Saiseikai Yokohamashi Tobu Hospital Takafumi Saito

**AOSO-32-4** Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma  
Department of Urology, Takatsuki General Hospital/Department of Urology, Osaka Medical and Pharmaceutical University Taizo Uchimoto

**AOSO-32-5** Comparison of enfortumab vedotin versus platinum re-challenge as later-line treatment for advanced urothelial carcinoma  
Department of Urology, Graduate School of Medicine, The University of Tokyo  
Satoru Taguchi

**AOSO-32-6** Cancer antigen vaccine enhances anti-tumor effects of immune checkpoint blockade against refractory cancers  
Department of Urology, Kyushu University School of Medicine Shohei Ueda

### AOS Oral Session 33

Saturday, October 21 10:45~11:25

Room17 (311+312, 3F, Conference Center, Pacifico Yokohama)

#### Biomarker 1 in lung cancer

Chair : Yukio Hosomi Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital

**AOSO-33-1** A novel resistance mechanism to NTRK inhibitors via HMGS2-induced mevalonate pathway  
Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School Yasuhiro Kato

**AOSO-33-2** Investigation of the Signal-regulatory protein alpha (SIRP $\alpha$ ), an immune checkpoint molecule, in lung squamous cell carcinoma  
Department of Surgery and Science, Kyushu University Taichi Nagano

**AOSO-33-3** Withdrawn

**AOSO-33-4** The Probability of Lung Cancer in Patients with Incidentally Detected Pulmonary Nodules Detected via Low-Dose Computed Tomography Screening in China

Department of Cancer Epidemiology and Prevention, Henan Engineering Research Center of Cancer Prevention and Control, Henan International Joint Laboratory of Cancer Prevention, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, People's Republic of China Lanwei Guo

**AOS Oral Session 34**

Saturday, October 21 11:30~12:10

Room17 (311+312, 3F, Conference Center, Pacifico Yokohama)

**Genome in lung cancer**

Chair : Hiroyuki Suzuki Department of Chest surgery, Fukushima Medical University

**AOSO-34-1** The current status of cancer genome testing in lung cancer diagnosis at Keio University Hospital

Department of Internal Medicine (Pulmonary Medicine), School of Medicine, Keio University/Cancer Center, School of Medicine, Keio University Hideki Terai

**AOSO-34-2** Clinical and Molecular Biomarker Profile and Early Survival Rate of Filipinos with Stage IIIB/IV Non-Small Cell, Non-Squamous Lung Cancer (CALMER Study)

Lung Cancer Study Group, The Medical City-Ortigas, Republic of the Philippines/Cancer CARE Registry and Research Philippines Foundation, Inc., Republic of the Philippines Beatrice J. Tiangco

**AOSO-34-3** EGFR Exon 19 Deletion Subtypes Do Not Influence Survival Outcomes Following First-Line EGFR-TKIs in Advanced NSCLC Patients

Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taiwan Yan-Jei Tang

**AOSO-34-4** CORRELATION BETWEEN HYPOXIA-INDUCED ACIDIFICATION AND CT TEXTURE IN NON-SMALL CELL LUNG CANCER

Inner Mongolia Baotou Tumor Hospital, People's Republic of China Ming Min Zhang

**AOS Oral Session 35**

Saturday, October 21 13:30~14:10

Room17 (311+312, 3F, Conference Center, Pacifico Yokohama)

**Others in urological cancer**

Chair : Norio Nonomura Department of Urology, Osaka University Graduate School of Medicine

**AOSO-35-1** A RARE CASE OF A HIGH-GRADE NON-FUNCTIONING ONCOCYTIC TYPE ADRENAL CORTICAL CARCINOMA

National Kidney and Transplant Institute, Republic of the Philippines Ma. Carmela Mananquil Maminta

- AOSO-35-2** Diagnostic accuracy of CT-guided core needle biopsy for metastatic lesions of urological cancer  
Department of Urology, Graduate School of Medicine, Osaka University  
Yu Ishizuya
- AOSO-35-3** REFRACTORY METASTATIC PRIMARY EXTRAGONADAL GERM CELL TUMOR TREATED WITH TANDEM HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN A PUBLIC HOSPITAL IN THE PHILIPPINES  
Section of Medical Oncology, National Kidney & Transplant Institute, Republic of the Philippines Anna Maree J. Bermudez
- AOSO-35-4** A machine learning model to predict the histology of retroperitoneal lymph node dissection specimens  
Department of Urology, Faculty of Medicine, University of Tsukuba  
Satoshi Nitta

### AOS Oral Session 36

Saturday, October 21 14:15~15:15

Room17 (311+312, 3F, Conference Center, Pacifico Yokohama)

#### Risk analysis and prediction for gastric cancer

Chair : Daisuke Ichikawa First Department of Surgery,  
Faculty of Medicine, University of Yamashashi

- AOSO-36-1** Withdrawn
- AOSO-36-2** What is gastric cancer with expression of both AFP and CEA?  
Department of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, People's Republic of China Weihua Gong
- AOSO-36-3** Proposal of a risk score system to predict death from other causes after resection of gastric cancer  
Department of Gastroenterological Surgery,  
Nagoya University Graduate School of Medicine Yuki Ito
- AOSO-36-4** Pathological Review of Resectable Gastric Cancer in a Tertiary Care Teaching Hospital in Nepal  
Tribhuvan University Teaching Hospital, Institute of Medicine, Kingdom of Nepal  
Prasan Bir Singh Kansakar
- AOSO-36-5** Comparison of postoperative outcomes and QOL surveys by surgical procedure in patients with upper gastric and esophagogastric junction cancer  
Department of General Surgical Science,  
Gunma University Graduate School of Medicine Akihiko Sano
- AOSO-36-6** Withdrawn

**AOS Oral Session 37**

Saturday, October 21 15:30~16:20

Room17 (311+312, 3F, Conference Center, Pacifico Yokohama)

**Biomarker 2 in lung cancer**Chair : Masahiro Seike Department of Pulmonary Medicine and Oncology,  
Graduate School of Medicine, Nippon Medical School**AOSO-37-1** Transcription factors and clinicopathological features define four subgroups in lung high-grade neuroendocrine tumorsDivision of General Thoracic Surgery, Integrative Center of General Surgery,  
Gunma University Hospital Ryohei Yoshikawa**AOSO-37-2** The farther tumor cells spread through air spaces, the worse prognosis in resected stage I adenocarcinomaDepartment of Surgery and Science, Graduate School of Medical Sciences,  
Kyushu University Asato Hashinokuchi**AOSO-37-3** MID-TERM OUTCOMES OF VIDEO-ASSISTED THORACOSCOPIC ANATOMICAL LUNG RESECTION FOR NON-SMALL CELL LUNG CANCER WITH CLINICAL STAGE I AND PROGNOSTIC FACTORSDepartment of Thoracic and Abdomen Surgery, Ho Chi Minh City Oncology Hospital,  
Socialist Republic of Viet Nam Vu Dinh Khanh Hoang**AOSO-37-4** Chronic stress promotes TGF- $\beta$  1-mediated epithelial interstitial transformation in lung cancerSixth People's Hospital South Campus, Shanghai Jiaotong University,  
People's Republic of China Feng Xu**AOSO-37-5** Predictive Value of Radiomics Parameters in Differentiating Benign and Malignant Lung Lesions

AIIMS Bhopal, Republic of India Rajesh Pasricha

**AOS Oral Session 38**

Saturday, October 21 11:10~12:00

Room18 (301, 3F, Conference Center, Pacifico Yokohama)

**Kidney cancer**

Chair : 座長変更予定★ ★Affiliation★

**AOSO-38-1** Risk factors for recurrence after curative nephrectomy in non metastatic renal cell carcinoma: A retrospective cohort studyDepartment of Internal Medicine, Section of Medical Oncology, National Kidney and  
Transplant Institute, Republic of the Philippines Kristine Geraneo Tejada**AOSO-38-2** The association between outcome and malnutrition score in hemodialysis associated renal cancer patientsDepartment of Urology, Faculty of Medicine,  
Osaka Medical and Pharmaceutical University Ryoichi Maenosono

**AOSO-38-3** Nivolumab usage patterns combined with TKI for mRCC: financial toxicity and clinical outcomes from self-paying patients in India. Is low dose an option when access is limited?

Department of Medical Oncology, Christian Medical College, Republic of India  
Jerryes Pious Wisely

**AOSO-38-4** The role of R.E.N.A.L Nephrometry Score to Predict Perioperative Outcome Following Partial Nephrectomy in Indonesia National Referral Hospital

Department of Urology, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo Hospital, Republic of Indonesia Adhitama Alam Soeroto

**AOSO-38-5** Considering the safe introduction of the hinotori surgical robot system, focusing on its differences from Da Vinci Xi

Department of Urology, Keio University School of Medicine Mio Tanigawa

### AOS Oral Session 39

Saturday, October 21 15:20~16:20

Room18 (301, 3F, Conference Center, Pacifico Yokohama)

#### Up to Date Head and Neck Cancer/Brain Tumor/Oral Cancer

Chair : Takahiro Asakage Department of Head and Neck Surgery,  
Tokyo Medical and Denatal University

**AOSO-39-1** Elucidation of associated factors related to postoperative oral dysfunction in oral cancer patients: structural equation modeling by cross-sectional study

Shimane University Faculty of Medicine,  
Department of Oral and Maxillofacial Surgery Yuhei Matsuda

**AOSO-39-2** Protocol for Preoperative steroid for enhancing patients' recovery after head and neck cancer surgery with free tissue reconstruction: a randomized-controlled study (J-SUPPORT-2022, PreSte-HN Study)

Department of Head and Neck Surgery, National Cancer Center Hospital East  
Takeshi Shinozaki

**AOSO-39-3** Dose-finding and efficacy confirmation trial of the superselective intra-arterial infusion of cisplatin and concomitant radiotherapy for maxillary sinus cancer (JCOG 1212): Results of the T4a cohort

Department of Otorhinolaryngology, Head and Neck Surgery Graduate School of  
Biomedical and Health Sciences, Hiroshima University Tsutomu Ueda



**AOSO-39-4** Prognostic value of Diffusion weighted Magnetic Resonance Imaging in Head and neck carcinoma to predict Local Control -prospective imaging biomarker study in a tertiary care institute

AIIMS Bhopal, Republic of India Aravind Padmanabhan

**AOSO-39-5** ERAS protocol for head and neck surgery and quality assessment of postoperative recovery

Department of Head and Neck Surgery, National Cancer Center Hospital East  
Kazuto Matsuura

**AOSO-39-6** New reconstruction methods after mandibulectomy

Department of Clinical Oral Oncology, National Hospital Organization,  
Hokkaido Cancer Center Takashi Niiyama

## AOS Oral Session 40

Saturday, October 21 8:30~9:30

Room19 (302, 3F, Conference Center, Pacifico Yokohama)

## Basic Research of Head and Neck Cancer/Brain Tumor/Oral Cancer 2

**Chair : Gracieux Yuzon Fernando** Division of Medical Oncology,  
Department of Medicine, College of Medicine,  
University of the Philippines-Manila -  
Philippine General Hospital,  
Republic of the Philippines

**AOSO-40-1** USP18 promotes Anlotinib resistance in medullary thyroid carcinoma by stabilizing Aurora B kinase

Tianjin Medical University Cancer Institute and Hospital, People's Republic of China/  
NanKai University, People's Republic of China Dapeng Li

**AOSO-40-2** A next-generation sequencing study on genetic changes in oral cancer development

Department of Oral and Maxillofacial Surgery, Nara Medical University  
Takahiro Yagyuu

**AOSO-40-3** T cell receptor repertoire analysis of oral lichen planus

Department of Oral and Maxillofacial Surgical Oncology, Graduate School of Medical  
and Dental Sciences, Tokyo Medical and Dental University Naoto Nishii

**AOSO-40-4** SLFN11 enhances the sensitivity to platinum-based chemoradiotherapy in head and neck squamous cell carcinoma

Department of Otolaryngology-Head and Neck Surgery Faculty of Medicine and  
Graduate School of Medicine, Hokkaido University Seihiro Hamada

**AOSO-40-5** lncRNA TRHDE-AS1 correlated with genomic landscape and clinical outcome in glioma

School of Public Health, Capital Medical University, People's Republic of China/  
National Institute for Data Science in Health and Medicine, Capital Medical University,  
People's Republic of China Jinxuan Xie

**AOSO-40-6** Long retention type novel boron carrier for boron neutron capture therapy in rat brain tumor models

Department of Neurosurgery, Osaka Medical and Pharmaceutical University  
Kohei Tsujino

**AOS Oral Session 41**

Saturday, October 21 9:40~10:40

Room19 (302, 3F, Conference Center, Pacifico Yokohama)

**Biliary tract carcinoma: Basic**

Chair : Li-Tzong Chen Department of Internal Medicine,  
Kaohsiung Medical University Hospital, Taiwan/  
Kaohsiung Medical University, Kaohsiung, Taiwan

**AOSO-41-1** Double Trouble in Gallbladder cancer: Heterogeneous ERBB activating pathways and proposed mechanisms of resistance

Department of Medical Oncology, INHS Asvini, Republic of India Amol Patel

**AOSO-41-2** The Utility of Comprehensive Genomic Profiling in Biliary Tract Cancer Patients: A Retrospective Study

Department of Medical Oncology, Kagawa University Hospital  
Hiroyuki Okuyama

**AOSO-41-3** MDM2 blockage in IDH1 mutated/TP53 wild-type intrahepatic cholangiocarcinoma (iCCA) cells

Institute of Basic Medical Sciences, National Cheng Kung University, Taiwan  
Chien-Tsung Liu

**AOSO-41-4** Examination of the correlation between tumor-infiltrating lymphocytes and PD-L1 expressions and prognosis in intrahepatic cholangiocarcinoma focusing on caveolin-1 and tumor microenvironment

Department of Gastroenterological Surgery, Graduate School of Medical Sciences,  
Kumamoto University Takashi Matsumoto

**AOSO-41-5** The impact of FGFR2 expression on prognosis in intrahepatic cholangiocarcinoma

Department of Surgery and Science, Graduate School of Medical Sciences,  
Kyushu University Katsuya Toshida

**AOSO-41-6** Indication for neoadjuvant therapy for resectable perihilar cholangiocarcinoma

Department of Surgery, Tohoku University Graduate School of Medicine  
Shuichi Aoki

**AOS Oral Session 42**

Saturday, October 21 10:55~11:45

Room19 (302, 3F, Conference Center, Pacifico Yokohama)

**Clinical Study for colorectal cancer**Chair : Motonobu Saito Department of Gastrointestinal Tract Surgery,  
Fukushima Medical University School of Medicine**AOSO-42-1** BREAKWATER: An open-label, randomized, phase 3 (ph 3) study, with a safety lead-in (SLI), of 1L encorafenib (E) + cetuximab (C) ± chemotherapy (CT) vs standard-of-care (SOC) for *BRAF V600E*-mutant mCRC

MD Anderson Cancer Center, United States of America Scott Kopetz

**AOSO-42-2** An effect of preoperative chemotherapy on micrometastases surrounding colorectal liver metastases -histological analysis of EXPERT study-Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery,  
Graduate School of Medicine, The University of Tokyo Masaru Matsumura**AOSO-42-3** Effect of dose-escalation protocol for capecitabine on dose in the fourth cycle of chemotherapy (Es-Cape 01)

Khon Kaen University, Kingdom of Thailand Thanit Imemkamon

**AOSO-42-4** The Methylation Level of Circulating Cell-free DNA Can Predict Recurrence of Colorectal CancerDepartment of Coloproctological Surgery, Juntendo University Faculty of Medicine  
Takahiro Irie**AOSO-42-5** The Usefulness of Circulating Cell-free DNA Methylation Status of Tumor Suppressor Genes in Precision Medicine for Stage IV Colorectal CancerDepartment of Coloproctological Surgery, Juntendo University Faculty of Medicine  
Kiichi Sugimoto**AOS Oral Session 43**

Saturday, October 21 13:30~14:30

Room19 (302, 3F, Conference Center, Pacifico Yokohama)

**Clinical Experience of Head and Neck Cancer/Brain Tumor/Oral Cancer 2**Chair : Kazuto Matsuura Division of Head and Neck Surgery,  
National Cancer Center Hospital East**AOSO-43-1** 18F-FDG-PET/CT parameters correlate with delayed neck metastasis in clinical early-stage oral squamous cell carcinomaDepartment of Oral and Maxillofacial Surgery, School of Medicine,  
Nara Medical University Hiroshi Nakamura

- AOSO-43-2** Comparison of various computer-assisted mandibular reconstruction methods after mandibular segmentectomy  
Department of Oral & Maxillofacial Oncology and Surgery, Osaka University, Graduate School of Dentistry Yoshihiro Morita
- AOSO-43-3** Computer-assisted functional and esthetic reconstruction of segmental mandibular defects  
Department of Oral and Maxillofacial Surgery, Shimane University Faculty of Medicine Tatsuo Okui
- AOSO-43-4** Treatment outcomes of sinonasal mucosal melanoma: usefulness of endoscopic surgery and postoperative radiotherapy  
Department of Otolaryngology- Head and Neck Surgery, Hokkaido University Graduate school of Medicine Nayuta Tsushima
- AOSO-43-5** Withdrawn
- AOSO-43-6** An observational study in Vietnamese patients with non-metastatic cutaneous malignant melanoma: patients' characteristic and outcome  
Hanoi Medical University, Socialist Republic of Viet Nam Chi Huyen Do

## AOS Oral Session 44

Saturday, October 21 14:45~15:25

Room19 (302, 3F, Conference Center, Pacifico Yokohama)

### Advanced cancers and supportive care

Chair : Etsuko Aruga Teikyo University School of Medicine, Department of Palliative Medicine

- AOSO-44-1** Estimated mortality rate following palliative radiotherapy in the COVID-19 Era: a retrospective single institution analysis  
Department of Radiology, the University of Tokyo Hospital Atsuto Katano
- AOSO-44-2** Efficacy of Oral Nutritional Supplement in Cancer Patients Receiving Chemotherapy: A Systematic Review and Meta- analysis of Randomized Controlled Trials  
Oncology Unit, Department of Medicine, Rajavithi Hospital, College of Medicine, Rangsit University, Kingdom of Thailand Photcharaphon Pintasiri
- AOSO-44-3** Withdrawn
- AOSO-44-4** Preparatory grief of young patients with advanced cancer and their relationship with hope, resilience, and coping style: A cross-sectional study  
Department of Integrated Traditional Chinese and Western Medicine, Tianjin Medical University Cancer Institute & Hospital, People's Republic of China  
Jie Jiao

**AOS Oral Session 45**

Saturday, October 21 15:40~16:20

Room19 (302, 3F, Conference Center, Pacifico Yokohama)

**Integrative medicine**

Chair : Tinh Huy Quoc Dang Board of Directors Ho Chi Minh City Oncology  
Hospital, Socialist Republic of Viet Nam

**AOSO-45-1 Cutting through Relapsed-Refractory Classical Hodgkin  
Lymphoma**

National Kidney and Transplant Institute, Republic of the Philippines  
Ma. Carmela Mananquil Maminta

**AOSO-45-2 A patient complicated with metastatic carcinoma of  
bone marrow during chemotherapy for anal canal cancer**

Department of Palliative Medicine, Teikyo University School of Medicine  
Atsuko Watanabe

**AOSO-45-3 Clinical characteristics of bloodstream infections in pa-  
tients with solid tumors and a nomogram for mortality  
prediction: a 5-year case-controlled retrospective study  
in a tertiary-level hospital**

School of Medicine, Xiamen University, People's Republic of China Lijuan Xue

**AOSO-45-4 Prognostic impact of Immune related adverse events  
(irAE) on survival in patients treated with checkpoint in-  
hibitors: A real-world experience from India**

Manipal Comprehensive Cancer Centre, Manipal Hospital, Republic of India  
Nitin Yashas Murthy